摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

卡利拉嗪杂质2 | 839712-25-3

中文名称
卡利拉嗪杂质2
中文别名
——
英文名称
1-trans-{4-[2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl]-cyclohexyl}carbamide
英文别名
1-trans {4-[2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]ethyl]-cyclohexyl}carbamide;trans-1-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-urea;Didesmethyl cariprazine;[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]urea
卡利拉嗪杂质2化学式
CAS
839712-25-3
化学式
C19H28Cl2N4O
mdl
——
分子量
399.364
InChiKey
UMTWXZNVNBBFLC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    200-205°C
  • 溶解度:
    可溶于DMSO(略微加热)、甲醇(略微加热)

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.63
  • 拓扑面积:
    61.6
  • 氢给体数:
    2
  • 氢受体数:
    3

制备方法与用途

去甲卡里普拉嗪是卡里普拉嗪的代谢产物,作为主要的循环活性成分。其半衰期较长,约为1至3周。卡里普拉嗪是一种新型抗精神病药物候选物,能结合D3、D2和5-HT1A受体。

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] PROCESS FOR THE PREPARATION OF PIPERAZINE COMPOUNDS AND HYDROCHLORIDE SALTS THEREOF
    [FR] PROCEDE DE PREPARATION DE COMPOSES DE PIPERAZINE ET SELS HYDROCHLORURES DE CEUX-CI
    摘要:
    公开号:
    WO2010070370A8
  • 作为产物:
    描述:
    三光气 、 trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexylamine dihydrochloride 在 三乙胺 作用下, 以 二氯甲烷甲醇 为溶剂, 反应 2.5h, 以94%的产率得到卡利拉嗪杂质2
    参考文献:
    名称:
    PROCESS FOR THE PREPARATION OF PIPERAZINE COMPOUNDS AND HYDROCHLORIDE SALTS THEREOF
    摘要:
    该发明涉及一种制备通式(I)化合物的新工艺,其中R1和R2分别表示氢或C1-6烷基,可以是直链或支链,也可以用芳基取代,或者是含有1-3个双键的C2-7烯基,或者是单环、双环或三环芳基,可以用一个或多个C1-6烷氧基、三氟甲氧基、C1-6-烷氧羰基、C1-6烷酰基、芳基、C1-6烷基硫基、卤素或氰基取代,或者是可选择取代的单环、双环或三环C3-14环烷基,R1和R2连同相邻的氮形成饱和或不饱和、可选择取代的单环或双环杂环,可以含有进一步选择的氧、氮或硫原子的杂原子,以及其盐和/或水合物和/或溶剂化合物,通过在惰性溶剂中溶解或悬浮式地将通式(III)的反式4-{2-[4-(2,3-二氯苯基)-哌嗪-1-基]-乙基}-环己胺或其盐或水合物或溶剂化合物,在碱存在下加入通式(VI)的碳酸衍生物,其中R是具有C1-6直链或支链的烷基或C1-2全氟化烷基,Z是-O-R或-X,其中R如上所述,X是卤素,然后与通式(V)的胺反应,其中R1和R2如上所述,以获得通式(I)的化合物,然后可选择形成其盐和/或水合物和/或溶剂化合物。
    公开号:
    US20110275804A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL PROCESS FOR THE PREPARATION OF PIPERAZINE COMPOUNDS AND HYDROCHLORIDE SALTS THEREOF<br/>[FR] NOUVEAU PROCÉDÉ POUR LA PRÉPARATION DE COMPOSÉS DE PIPÉRAZINE ET DE SELS CHLORHYDRATES DE CEUX-CI
    申请人:RICHTER GEDEON NYRT
    公开号:WO2011073705A1
    公开(公告)日:2011-06-23
    The invention relates to a new process for the preparation of compounds of general formula (I) wherein R1 and R2 represent independently hydrogen or C1-6 alkyl with straight or branched chain optionally substituted with aryl group; or C2-7 alkenyl containing 1-3 double bonds; or monocyclic, bicyclic or tricyclic aryl optionally substituted with one or more C1-6 alkoxy, trifiuoro-C1-6 alkoxy, C1-6-alkoxycarbonil, C1-6alkanoyl, aryl, C1-6 alkylthio, halogen or cyano; or optionally substituted monocyclic, bicyclic or tricyclic C3-14 cycloalkyl group; R1 and R2 together with the adjacent nitrogen form a saturated or unsaturated optionally substituted monocyclic or bicyclic heterocyclic ring which may contain further heteroatoms selected from oxygen, nitrogen, or sulphur atoms and hydrochloric acid salts and/or hydrates and/or solvates thereof, by dissolving or suspending trans 4-2-[4-(2,3-dichlorophenyl)-piperazine-1-il]-ethyl}-cyclohexylamine of formula (III) or a salt or a hydrate or a solvate thereof in an inert solvent in the presence of a base then adding a carbonic acid derivative of general formula (VI) wherein R is alkyl with C1-6 straight or branched chain, partially or fully halogenated C1-2 alkyl or phenyl, Z is -O-R or -X, wherein R is as described above, X is halogen, and reacting the compound of general formula (IV) obtained wherein R is as described above, in situ or, optionally in isolated state with an amine of general formula (V) wherein R1 and R2 are as described above to obtain the compound of general formula (I) and then optionally forming the hydrochloride salts and/or hydrates and/or solvates thereof.
    本发明涉及一种新的制备通式(I)化合物的方法,其中R1和R2分别表示氢或C1-6直链或支链烷基,可选择地取代芳基;或含有1-3个双键的C2-7烯基;或单环、双环或三环芳基,可选择地取代一个或多个C1-6烷氧基、三氟甲基-C1-6烷氧基、C1-6-烷氧羰基、C1-6-烷酰基、芳基、C1-6烷硫基、卤素或氰基;或可选择地取代的单环、双环或三环C3-14环烷基;R1和R2与相邻的氮一起形成饱和或不饱和的、可选择地取代的单环或双环杂环环,该环可能包含进一步从氧、氮或硫原子中选择的杂原子以及其氯化氢盐和/或水合物和/或溶剂化合物,通过在惰性溶剂中溶解或悬浮通式(III)的反式4-2-[4-(2,3-二氯苯基)-哌嗪-1-基]-乙基}-环己基胺,或其盐或水合物或溶剂化合物,在碱存在下添加通式(VI)的碳酸衍生物,其中R为C1-6直链或支链烷基、部分或完全卤代的C1-2烷基或苯基,Z为-O-R或-X,其中R如上所述,X为卤素,并将所得的通式(IV)化合物在原位或可选地在分离状态下与通式(V)的胺反应,其中R1和R2如上所述,以获得通式(I)的化合物,然后可选择地形成其氯化氢盐和/或水合物和/或溶剂化合物。
  • (THIO) Carbamoyl-Cyclohexane Derivatives as D3/D2 Receptor Antagonists
    申请人:Csongor Eva Againe
    公开号:US20100240640A1
    公开(公告)日:2010-09-23
    The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R 1 and R 2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R 1 and R 2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
    本发明涉及一种新的D3和D2多巴胺受体亚型偏好配体,其化学式为(I):其中R1和R2分别表示从氢,烷基,芳基,环烷基,芳酰基中选择的取代基,或者R1和R2可以与相邻的氮原子形成杂环;X表示氧或硫原子;n是1到2的整数,以及它们的几何异构体和/或立体异构体和/或对映异构体和/或盐和/或水合物和/或溶剂化物,以及制备它们的过程,含有它们的制药组合物以及它们在治疗和/或预防需要调节多巴胺受体的疾病中的应用。
  • (THIO) Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
    申请人:Csongor Againe Eva
    公开号:US20060229297A1
    公开(公告)日:2006-10-12
    The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R 1 and R 2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R 1 and R 2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
    本发明涉及公式(I)的新的D3和D2多巴胺受体亚型偏好配体,其中R1和R2分别表示从氢,烷基,芳基,环烷基,芳香基或R1和R2可以与相邻的氮原子形成杂环环;X表示氧原子或硫原子;n为1到2的整数,以及它们的几何异构体和/或立体异构体和/或对映异构体和/或盐和/或水合物和/或溶剂化物,以及制备它们的过程,含有它们的制药组合物以及它们在调节多巴胺受体所需的治疗和/或预防疾病中的使用。
  • [EN] PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES<br/>[FR] MÉTHODE DE PRÉPARATION DE DÉRIVÉS DE PIPÉRAZINE
    申请人:RICHTER GEDEON NYRT
    公开号:WO2010070371A8
    公开(公告)日:2011-04-28
  • (THIO)CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS
    申请人:Richter Gedeon Nyrt.
    公开号:EP1663996B1
    公开(公告)日:2012-06-20
查看更多